Literature DB >> 30072413

No longer too exhausted to run.

John G Gribben1.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 30072413      PMCID: PMC6073321          DOI: 10.1182/blood-2018-06-851642

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

2.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Authors:  Hagop Kantarjian; Anthony Stein; Nicola Gökbuget; Adele K Fielding; Andre C Schuh; Josep-Maria Ribera; Andrew Wei; Hervé Dombret; Robin Foà; Renato Bassan; Önder Arslan; Miguel A Sanz; Julie Bergeron; Fatih Demirkan; Ewa Lech-Maranda; Alessandro Rambaldi; Xavier Thomas; Heinz-August Horst; Monika Brüggemann; Wolfram Klapper; Brent L Wood; Alex Fleishman; Dirk Nagorsen; Christopher Holland; Zachary Zimmerman; Max S Topp
Journal:  N Engl J Med       Date:  2017-03-02       Impact factor: 91.245

Review 3.  How and when I do allogeneic transplant in CLL.

Authors:  John G Gribben
Journal:  Blood       Date:  2018-05-11       Impact factor: 22.113

4.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

5.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

6.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

7.  A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.

Authors:  Hannah R Robinson; Junpeng Qi; Erika M Cook; Cydney Nichols; Eman L Dadashian; Chingiz Underbayev; Sarah E M Herman; Nakhle S Saba; Keyvan Keyvanfar; Clare Sun; Inhye E Ahn; Sivasubramanian Baskar; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2018-05-09       Impact factor: 22.113

8.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

  8 in total
  2 in total

1.  Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

Authors:  Mazyar Shadman; David G Maloney; Barry Storer; Brenda M Sandmaier; Thomas R Chauncey; Niels Smedegaard Andersen; Dietger Niederwieser; Judith Shizuru; Benedetto Bruno; Michael A Pulsipher; Richard T Maziarz; Edward D Agura; Parameswaran Hari; Amelia A Langston; Michael B Maris; Peter A McSweeney; Rainer Storb; Mohamed L Sorror
Journal:  Bone Marrow Transplant       Date:  2019-09-03       Impact factor: 5.483

2.  BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Authors:  Maissa Mhibik; Erika M Gaglione; David Eik; Ellen K Kendall; Amy Blackburn; Keyvan Keyvanfar; Maria Joao Baptista; Inhye E Ahn; Clare Sun; Junpeng Qi; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2021-11-11       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.